Regenerative Medical Technology (RMTG) Operating Expenses (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Operating Expenses of $1.5 million for Q1 2026, up 89.97% year-over-year from $808934.0 in Q1 2025, and up 41.53% quarter-over-quarter from $1.1 million in Q4 2025.
Regenerative Medical Technology (RMTG) Operating Expenses (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's Operating Expenses history runs 9 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 89.97% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $4.4 million (up 53.15% YoY), while the FY2025 annual figure was $3.7 million, up 34.14% from the prior year.
- Operating Expenses for Q1 2026 stood at $1.5 million, up from $1.1 million in the prior quarter.
- The five-year high for Operating Expenses was $2.8 million in Q4 2022, with the low at $426578.0 in Q3 2022.
- The 5-year median for Operating Expenses is $684665.0 (2023), against an average of $867720.8.
- Peak annual rise in Operating Expenses reached 388.36% in 2022, while the deepest fall reached 95.31% in 2022.
- Regenerative Medical Technology's Operating Expenses stood at $2.8 million in 2022, then slumped by 79.76% to $569861.0 in 2023, then advanced by 5.21% to $599565.0 in 2024, then surged by 81.09% to $1.1 million in 2025, then surged by 41.53% to $1.5 million in 2026.
- Business Quant data shows RMTG's Operating Expenses at $1.5 million in Q1 2026, $1.1 million in Q4 2025, and $947318.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 541.02 Mn |
| 10 | Regenerative Medical Technology | 814,616.00 | -246,832.00 | 1.77 Mn | 1.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 947,318.00 |
| Jun 30, 2025 | 835,918.00 |
| Mar 31, 2025 | 808,934.00 |
| Dec 31, 2024 | 599,565.00 |
| Sep 30, 2024 | 727,413.00 |
| Jun 30, 2024 | 740,865.00 |
| Mar 31, 2024 | 674,096.00 |
| Dec 31, 2023 | 569,861.00 |
| Sep 30, 2023 | 525,356.00 |
| Jun 30, 2023 | 684,665.00 |
| Mar 31, 2023 | 611,012.00 |
| Dec 31, 2022 | 2.82 Mn |
| Sep 30, 2022 | 426,578.00 |
| Jun 30, 2022 | 512,592.00 |
| Mar 31, 2022 | 648,654.00 |
| Dec 31, 2021 | 576,618.00 |
| Sep 30, 2021 | 9.09 Mn |
| Jun 30, 2021 | 258,420.00 |